Study found 86% of patients preferred it to IV formulation. The FDA approved a subcutaneous version of trastuzumab (Herceptin) for treating HER2-positive breast cancer on Thursday.
Two randomized trials confirmed the safety and efficacy of the new formulation, which combines the anti-HER2 targeted agent with hyaluronidase, an endoglycosidase, and will be branded Herceptin Hylecta. Read More
To refresh the top news stories, click here.
Bosom Buddies, Inc. is a501(c)3 non-profit organization.
Bosom Buddies of Arizona
Sign up for our newsletter and stay atop all the goings on with our support groups and their efforts. You can unsubscribe anytime.